A questionnaire w a s sent t o 240 adult w o m e n previo u s l y treated f o r extremely tall stature. 2 0 2 (84.2%) responded. T h e i r m e a n a g e w a s 21.0 + 1.9 (SD) years.
157 w o m e n recalled, that they w e r e extremely tall already i n childhood w i t h growth related problems described b y 8 9 o f them. F o r t h e majority expected and/ o r actual height problems w e r e the reasons for treatment. T h e considerable weight gain during therapy w a s t h e m o s t frequently mentioned side-effect. Today, 186 w o m e n h a v e a positive o r mostly positive a n d only 9 a negative attitude towards their present height (180.6 + 4.2 cm). S o m e height related problems w i t h clothes, furniture, public appearance etc. still existed i n about 1 0 -3 0 % o f them. Questioned about their "ideal height" most women wished t o b e 175.4 + 3.8 cm. 176 w o m e n responded w i t h "yes" t o the question, if they would positively reconsider treatment. Thus, therapy f o r tall stature meets w i t h general approval i n m o s t treated women. 14 inke ink el*, .J.~rand* (Introd. by R. Illig)
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INFLUENCE OF LOW DOSES OF ANABOLICS ON GROWTH, DEVELOPMENT AND PERFORMANCE OF CHILDREN AN0 YOUTH WITH CONSTITUTIONAL GROWTH RETARDATION (CGR)
In a long-term study 66 boys with CGR and psychosocial problems were treated with low doses of 4-chlor-dehydro-methyltestosterone (0,l mg per kg body weight for 8 weeks, intervals of 4 weeks) for 2,7 2 1,3 years and followed up to the 20th year of life. A control group without such treatment included 26 boys.
Results: 1. Skeletal maturity at the beginning of therapy and difference of final and predicted body height show a negative correlation. If therapy starts at bone age of less than 10 years the predicted height will not be reached (-6,l 2 7,3 cm).
On the contrary predicted height is not diminished when treatment with anabolics starts when the bone age is 10 years or more (-0,5 ' 3,3 cm).
2. Matched pairs of 19 treated boys with an identical control group (bone age of 10 years or more at beginning of the therapy) revealed no difference of the predicted and final body height at the age of 20 years.
Z. Dickerman, R.J. Barkey*l, R. 3.7 mIU/ml respectively in mafched controls). At spontaneous termination of puberty, 3 4 yrs following referral, with still low IR-LH, their LH bioactivity was compared with that of 8 matched controls, using a rat leydig cell bioassay system with LER-907 (NPA) as standard. The plasma LH bioactivity was estimated to be .33+.1 and .2+.05 for the basal LH and .8+.2 and .83+.2 mIU/ml for-the LRH-sFimul ated plasma in both groups, respecfively. The ratio of the LH-bioactivity to IR-LH was found to be higher in the patients (1.895.4) than in the control group (.8+-1, p<.05). In 3 of the patients low IR-LH levels were found arso during sleep, with no significant change from the wake time IR-LH plasma levels.
The plasma testosterone levels of the patients were normal (400t80 ng/dl ) and increased following a prolonged LRH stimul ation-(500 mcg iv over 3 hrs) in 4 of the patients (530560 ng/dl).
It is concluded, that in some boys with delayed puberty consistently low IR-LH plasma levels with normal LH-bioactivi ty may be found. In 4 patlents wlth a slgnlf lcant pre-treatment nocturnal LH rlse, pul sat1 le GnRH stlmulatlon dld not slgnf lcant ly Increme endogenous LH pulse frequemy or amplitude. In 4 subJects wlth probable Kallmann's s y n 6 m or ldlopathlc hypogona&trophlc hypogonadlsm, responses to I/V GnRH lncremed 6amatlcal ly (LH 5.6A0.5 fold, FSH 6.5+ 2.3 fold). In 2 of then no LH pulses were observed before or after GnRH prlmlng and only FSH pulses (4/12h and 1/12h) post-stlmulatlon. In the other 2, LH pulses Increased from zero to 7/12h and 3 to 6/8h respectively. These data show that nocturnal pulsatlle GnRH prlmlng can augnelrt pltultary responslveness @ Increase the number of detectable gonadotrophin secretory splsodes cnly In prepubertal pat lents wlthout pre-exlstlng nocturnal LH elevation. Increasing GnRH pulse awl ltuds may be a maJor mechanlsm In pubertal Inltlatlon. Short term pulsatlleGnRH prlmlng may be useful In dlstlngulshlng permanent hypogonadotrophlc hypogonadlsm fran constltutlonally del ayed puberty. Low plasma oestradiol concentrations are difficult to determine for a number of reasons of which the bridge recognition phenomenon (iodination at the same locus as the site for hapten formation) is one factor which limits assay sensitivity. Hence using an antibody to oestradiol-6-CMO-BSA and homologous label (oestradiol -6-iodohistamine) the "minimal detectable concentration" is l8pmol /L even with measurements in triplicate. We have evaluated a heterologous configuration at the site of attachment of oestradiol to the antibody ( o e s t r a d i o l -l~~-s u c c i n y l -~~~) and the label (oestradiol-11Crtyrosine methyl ester). With some antibodies this gave 3-4 fold increase in sensitivity although in certain cases the assay specificity was compromised by cross reaction (16%) with oestrone.
Serum concentrations of gonadotrophins and oestradiol at 15 minute intervals throughout the night have been determined in 8 girls with central precocious puberty treated with D-Ser-GnRH analogue (Hoechst) and in 14 girls with delayed puberty treated with nocturnal pulsatile GnRH. We have observed a rise in oestradiol after the third or fourth LH pulse just as in normal girls (Boyar, 1974) . This contrasts with our findings in boys in early puberty in whom testosterone rose after the first nocturnal Lli pulse. These findings are important to the timing of blood samples to assess sex steroid secretion during puberty.
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